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Most anticancer drugs work by triggering tumour cells to undergo programmed cell death, or apoptosis. However, many 
tumour cells activate a stress response in an 
attempt to combat the effects of the drugs. To 
date, most studies that have examined this 
response have focused on how the drugs affect 
the production of messenger RNA (mRNA) via tran-
scription in the tumour cells, and much less is 
known about the effects of these drugs on the 
translation of the mRNA, or on proteins. Now, in 
eLife, James Wells of the University of California, 
San Francisco and co-workers—including Arun 
Wiita as first author—use a new approach to 
study changes in transcription, translation and 
protein degradation in tumour cells exposed to 
an anticancer drug. They show that by targeting 
key regulators of the stress response, they can 
lower the threshold for triggering apoptosis in 
the tumour cells (Wiita et al., 2013).
To study apoptosis in detail, Wiita et al. used a 
systems-level approach to examine transcription, 
translation and protein degradation (proteolysis) 
in a myeloma cell line—a type of cancer of white 
blood cells—exposed to an anticancer drug 
called bortezomib. They paired mRNA sequencing 
with a technique called ribosome profiling, in which 
the presence of a ribosome bound to mRNA 
(a ‘footprint’) is used to reveal which mRNAs are 
being translated. This technique has proven to 
be indispensable for the genome-wide study of 
translation (Ingolia et al., 2009). Wiita et al. used 
an additional suite of tools to study the abundance 
of proteins and the rate at which they were broken 
down by apoptotic proteases (Mahrus et al., 
2008; Agard et al., 2012).
By comparing the number of ribosome foot-
prints with the number of mRNA sequencing 
reads, it was possible to deduce the efficiency 
of translation within the tumour cells (Figure 1). 
In line with previous reports, they found that 
bortezomib—which inhibits a complex called 
the proteasome—caused misfolded proteins to 
accumulate inside cells. As a result, the endo-
plasmic reticulum (which is involved in protein 
trafficking) became overwhelmed, triggering the 
unfolded protein response (Obeng et al., 2006). 
This leads to a series of cellular processes to 
counteract the accumulation of misfolded pro-
teins, including increased protein folding, inhi-
bition of translation, and, as a last resort, the 
induction of apoptosis. Witta et al. showed that 
bortezomib increased both transcription and trans-
lation of a number of genes involved in the folding 
or degradation of proteins, and downregulated 
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the expression of genes involved in cellular 
proliferation.
The coding sequence of genes is preceded by 
an upstream regulatory region called the 5′-leader. 
Ribosomes have frequently been shown to initiate 
translation from within this 5′-leader when cells 
are exposed to oxidative stress (Gerashchenko 
et al., 2012) or undergo differentiation (Ingolia 
et al., 2011), thereby providing another level of 
translational control. Ribosome occupancy of 
the 5′-leader sequence may indicate the trans-
lation of short regulatory polypeptides encoded 
by upstream open reading frames, or point to the 
expression of alternative isoforms of the protein 
extended at the N-terminus (Ingolia et al., 2011). 
Wiita et al. found that genes whose expression 
was regulated by bortezomib showed altered 
translation from the 5′-leader compared to non-
regulated genes. Nevertheless, despite the rela-
tively large changes in mRNA and footprint reads 
that were seen across the tumour cell genes, the 
vast majority of proteins showed no changes in 
their relative abundance, as inferred from quanti-
tative proteomics data.
Based on estimates of the absolute levels of 
transcripts and proteins, Wiita et al. then devised 
a model to account for the limited changes in 
protein levels relative to those of mRNA and 
mRNA-translation events. Their proposed ‘mass-
action model of translation’ describes changes in 
the number of copies of a protein per cell as a 
function of the number of copies of a transcript 
per cell, as well as the rates of mRNA translation 
and protein degradation. The model demonstrates 
that increases in the abundance of proteins tend 
to be coupled to increases in absolute transcript 
levels, and implies that for the same increase in 
relative transcript levels, low abundance proteins 
will undergo a larger increase in relative protein 
abundance than will high abundance proteins. 
Finally, the results of Wiita et al. revealed that 
proteins that were upregulated in response to 
bortezomib were not preferentially processed by 
proteases relative to other proteins, suggesting 
that the changes in transcription and translation 
do not affect the dynamics of protein processing 
once apoptosis ensues.
Myeloma cells produce large quantities of 
antibodies and have therefore adapted to cope 
with an increased burden of secretory protein 
synthesis and folding, but these changes have also 
made them particularly sensitive to the effects of 
proteasome inhibition. Although cells can adapt to 
protein folding insults following chronic exposure 
(Jager et al., 2012), the acute nature of borte-
zomib treatment is likely to prevent such adapta-
tion, despite the translational re-programming 
observed in bortezomib treated myeloma cells. 
Adaptation has also been linked to low levels of 
activation of the stress response and a distinct 
pattern of protein expression (Rutkowski et al., 
2006). Since adaptation could underlie the ability 
of cells to become resistant to chemotherapy, it 
would be interesting to compare the responses of 
resistant and sensitive cells. It also remains to be 
explored how the actions of bortezomib relate 
to those of other chemotherapeutic drugs and 
other apoptosis inducing agents. Overall, it is 
likely that efforts to integrate the transcrip-
tome, translatome, proteome and degradome 
Figure 1. A schematic to show how translation 
efficiency can be assessed by means of ribosome 
profiling. The production of a protein from a gene 
involves transcription, which can be measured in terms 
of mRNA sequence reads (red), and translation, which 
can be measured in terms of ribosome footprints (blue). 
(A) Relative to a baseline condition (top), bortezomib 
increases both the transcription and the translation of 
certain genes, as can be seen from the mRNA levels 
and the ribosome footprints (bottom). (B) Bortezomib 
can also decrease both transcription and translation. 
For other genes, bortezomib had differing effects on 
these two processes: an increase in protein levels relative 
to baseline, despite a reduction in mRNA, indicates that 
the efficiency of translation is increased (C); and a 
reduction in protein levels relative to baseline, despite 
no change in mRNA, indicates that the efficiency of 
translation is reduced (D).
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responses will typify future systems biology 
research and lead to new molecular insights into 
cancer and the drugs used to treat it.
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